Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9478240 | 0.88 | GRM5 (0.55) | GRM5TYRMEN1ALDH1A1KMT2A | |
| SCHEMBL11081773 | 0.87 | MAPT (0.58) | GRM5TYRMEN1ALDH1A1GAA | |
| SCHEMBL17866111 | 0.85 | KMT2A (0.56) | MEN1ALDH1A1GAAALOX15HTT | |
| SCHEMBL18669089 | 0.84 | KDM4E (0.67) | GRM5P2RX7MEN1ALDH1A1GAA | |
| SCHEMBL13077677 | 0.84 | RPS6KA2 (0.50) | TYRMEN1ALDH1A1GAAALOX15 | |
| SCHEMBL6076008 | 0.84 | GRM5 (0.62) | GRM5MEN1ALDH1A1GAAALOX15 | |
| SCHEMBL2558741 | 0.84 | GRM5 (0.52) | GRM5TYRCASP3 | |
| SCHEMBL29629115 | 0.84 | GRM5 (0.52) | GRM5TYRCASP3 | |
| SCHEMBL3729405 | 0.84 | TYR (0.49) | GRM5TYRMEN1ALDH1A1GAA | |
| SCHEMBL10339317 | 0.82 | TYR (0.64) | GRM5TYRMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | GRM5 1721/4885P2RX7 9/4885TYR 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.